Rhenman & Partners Asset Management Ab Novo Cure LTD Transaction History

Rhenman & Partners Asset Management Ab

$1.2 Billion
Q3 2024

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	BUY	$12.42 - $17.29 $4.16 Million - $5.8 Million	335,307 Added 209.57%	495,307 $7.74 Million
Q4 2023 Feb 13, 2024	BUY	$11.13 - $15.78 $1.78 Million - $2.52 Million	160,000 New	160,000 $2.39 Million
Q1 2023 May 11, 2023	BUY	$56.44 - $118.81 $564,400 - $1.19 Million	10,000 Added 28.57%	45,000 $2.71 Million
Q3 2022 Nov 14, 2022	SELL	$67.99 - $89.57 $1.7 Million - $2.24 Million	-25,000 Reduced 41.67%	35,000 $2.47 Million
Q2 2022 Aug 12, 2022	SELL	$56.6 - $89.9 $549,020 - $872,030	-9,700 Reduced 13.92%	60,000 $4.17 Million
Q1 2022 May 13, 2022	SELL	$60.15 - $84.52 $3.05 Million - $4.28 Million	-50,687 Reduced 42.1%	69,700 $5.78 Million
Q4 2021 Feb 11, 2022	BUY	$75.08 - $121.99 $4.53 Million - $7.37 Million	60,387 Added 100.65%	120,387 $9.61 Million
Q3 2021 Nov 12, 2021	SELL	$116.17 - $194.55 $6.97 Million - $11.7 Million	-60,000 Reduced 50.0%	60,000 $6.97 Million
Q2 2021 Aug 13, 2021	SELL	$130.4 - $225.58 $7.82 Million - $13.5 Million	-60,000 Reduced 33.33%	120,000 $26.6 Million
Q1 2021 May 14, 2021	BUY	$124.11 - $190.17 $7.45 Million - $11.4 Million	60,000 Added 50.0%	180,000 $23.8 Million
Q4 2020 Jan 19, 2021	SELL	$112.16 - $174.14 $32.5 Million - $50.4 Million	-289,600 Reduced 70.7%	120,000 $20.8 Million
Q3 2020 Oct 13, 2020	BUY	$58.05 - $111.31 $2.01 Million - $3.85 Million	34,600 Added 9.23%	409,600 $45.6 Million
Q2 2020 Jul 16, 2020	BUY	$57.2 - $74.41 $858,000 - $1.12 Million	15,000 Added 4.17%	375,000 $22.2 Million
Q1 2020 Apr 16, 2020	BUY	$57.05 - $95.75 $570,500 - $957,500	10,000 Added 2.86%	360,000 $24.2 Million
Q4 2019 Jan 17, 2020	BUY	$68.3 - $93.8 $683,000 - $938,000	10,000 Added 2.94%	350,000 $29.5 Million
Q3 2019 Oct 16, 2019	SELL	$61.86 - $97.8 $1.6 Million - $2.53 Million	-25,899 Reduced 7.08%	340,000 $25.4 Million
Q2 2019 Jul 22, 2019	SELL	$42.22 - $63.23 $3.75 Million - $5.61 Million	-88,748 Reduced 19.52%	365,899 $23.1 Million
Q1 2019 Apr 11, 2019	SELL	$31.96 - $56.12 $2.89 Million - $5.07 Million	-90,353 Reduced 16.58%	454,647 $21.9 Million
Q4 2018 Feb 05, 2019	BUY	$28.72 - $52.63 $4.16 Million - $7.63 Million	145,000 Added 36.25%	545,000 $18.2 Million
Q3 2018 Oct 03, 2018	SELL	$32.0 - $52.4 $1.6 Million - $2.62 Million	-50,000 Reduced 11.11%	400,000 $21 Million
Q2 2018 Jul 20, 2018	BUY	$19.85 - $32.0 $297,750 - $480,000	15,000 Added 3.45%	450,000 $14.1 Million
Q1 2018 Apr 11, 2018	SELL	$19.3 - $23.65 $628,581 - $770,256	-32,569 Reduced 6.97%	435,000 $9.48 Million
Q4 2017 Jan 19, 2018	SELL	$16.3 - $21.9 $3.24 Million - $4.36 Million	-198,959 Reduced 29.85%	467,569 $9.45 Million
Q3 2017 Oct 13, 2017	BUY	$18.05 - $21.75 $12 Million - $14.5 Million	666,528	666,528 $13.2 Million

Others Institutions Holding NVCR

# of Institutions

262

Shares Held

77M

Call Options Held

1.17M

Put Options Held

318K

Black Rock Inc. New York, NY

12.1M
Shares

$215 Million
0.0% of portfolio
Vanguard Group Inc Valley Forge, PA

11.8M
Shares

$210 Million
0.0% of portfolio
Capital International Investors Los Angeles, CA

7.92M
Shares

$140 Million
0.02% of portfolio
Capital World Investors Los Angeles, CA

4.31M
Shares

$76.4 Million
0.01% of portfolio
Nordwand Advisors, LLC Radnor, PA

3.03M
Shares

$53.7 Million
12.67% of portfolio

View Full List

About NovoCure Ltd

Ticker NVCR
Exchange NASDAQ
Sector Healthcare
Industry Medical Instruments & Supplies
Shares Outstandng 104,950,000
Market Cap $1.86B
Description
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optu...

More about NVCR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhenman & Partners Asset Management Ab, based on Form 13F filings with the SEC.

News

Stay updated on Rhenman & Partners Asset Management Ab with notifications on news.

Account